{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:07:03Z","timestamp":1762780023455,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40268-024-00493-3","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T06:58:54Z","timestamp":1730185134000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study"],"prefix":"10.1007","volume":"24","author":[{"given":"Caiyun","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3325-3437","authenticated-orcid":false,"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"4","key":"493_CR1","volume":"15","author":"B Katta","year":"2023","unstructured":"Katta B, Vijayakumar C, Dutta S, Dubashi B, Nelamangala Ramakrishnaiah VP. The incidence and severity of patient-reported side effects of chemotherapy in routine clinical care: a prospective observational study. Cureus. 2023;15(4): e38301.","journal-title":"Cureus"},{"issue":"24","key":"493_CR2","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"issue":"10","key":"493_CR3","first-page":"655","volume":"54","author":"D Chandrasekar","year":"2004","unstructured":"Chandrasekar D, Ramakrishna S, Diwan PV. A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. Arzneimittelforschung. 2004;54(10):655\u20139.","journal-title":"Arzneimittelforschung"},{"issue":"1\u20132","key":"493_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchromb.2008.02.002","volume":"864","author":"K Liu","year":"2008","unstructured":"Liu K, Dai X, Zhong D, Chen X. Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864(1\u20132):129\u201336.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"493_CR5","unstructured":"Technical guidelines for bioequivalence research of chemical drugs and generic drugs in human body with pharmacokinetic parameters as the end point evaluation index. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=e3835d476d956df4b8a2bf543daf277f. https:\/\/www.cde.org.cn\/."},{"issue":"5","key":"493_CR6","first-page":"386","volume":"2","author":"Z Zhang","year":"2002","unstructured":"Zhang Z, Zou Q, Li W, Yan L, Xiang B, Wu R. Determination of ondansetron in human plasma by rp-hplc. Chin J Pharmaceut Anal. 2002;2(5):386\u20138.","journal-title":"Chin J Pharmaceut Anal"},{"issue":"8","key":"493_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.2042-7158.1996.tb03973.x","volume":"48","author":"KH Simpson","year":"1996","unstructured":"Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron: a review. J Pharm Pharmacol. 1996;48(8):774\u201381.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"493_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2001.tb00195.x","volume":"7","author":"JH Ye","year":"2001","unstructured":"Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-ht(3) receptor antagonist and its applications in cns-related disorders. CNS Drug Rev. 2001;7(2):199\u2013213.","journal-title":"CNS Drug Rev"},{"issue":"2","key":"493_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","volume":"29","author":"F Roila","year":"1995","unstructured":"Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995;29(2):95\u2013109.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"493_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/ph16121693","volume":"16","author":"F Alqahtani","year":"2023","unstructured":"Alqahtani F, Alruwaili AH, Alasmari MS, Almazroa SA, Alsuhaibani KS, Rasool MF, Alruwaili AF, Alsanea S. A physiologically based pharmacokinetic model to predict systemic ondansetron concentration in liver cirrhosis patients. Pharmaceut (Basel). 2023;16(12):1693.","journal-title":"Pharmaceut (Basel)"},{"issue":"12","key":"493_CR11","first-page":"603","volume":"33","author":"H Zheng","year":"2002","unstructured":"Zheng H, Pan W, Wang Y, Mao S, Bi D. Determination of ondansetron hydrochloride in human plasma by hplc. Chin J Pharmaceut. 2002;33(12):603\u20135.","journal-title":"Chin J Pharmaceut"},{"issue":"1","key":"493_CR12","first-page":"55","volume":"32","author":"Y Wang","year":"2005","unstructured":"Wang Y, Wu W, Huang M, Hu T, Sun Y, Que L. Bioavailability and bioequivalence of ondansetron orally disintegrating tablets and conventional tablets. Fudan Univ J Med Sci. 2005;32(1):55\u20138.","journal-title":"Fudan Univ J Med Sci"},{"issue":"9","key":"493_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jat\/34.9.581","volume":"34","author":"F Musshoff","year":"2010","unstructured":"Musshoff F, Madea B, Stuber F, Stamer UM. Enantioselective determination of ondansetron and 8-hydroxyondansetron in human plasma from recovered surgery patients by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2010;34(9):581\u20136.","journal-title":"J Anal Toxicol"},{"issue":"3","key":"493_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/j.1552-4604.1996.tb04190.x","volume":"36","author":"WD Figg","year":"1996","unstructured":"Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol. 1996;36(3):206\u201315.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"493_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2125.1993.tb04164.x","volume":"35","author":"JC Blake","year":"1993","unstructured":"Blake JC, Palmer JL, Minton NA, Burroughs AK. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. Br J Clin Pharmacol. 1993;35(4):441\u20133.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00493-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:12:14Z","timestamp":1734491534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00493-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00493-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"23 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was suppported by Shijiazhuang No. 4 Pharmaceutical Co.,Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets used or analyzed are available from Zhanjun Dong upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and code availability"}},{"value":"This study protocol was approved by the Ethics Committee of Hebei Provincial People's Hospital (approval number: HBRM-H-067, 2021-24-01) and registered in the Chinese Clinical Trial Register (ChiCTR) with registration number CTR20213116 ( #CTR20213116).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Conception and study designing: WJB and ZJD. Data acquisition: CYJ. Analysis and interpretation: NZ, HJS, YTH, and YFX. Drafting of the manuscript: CYJ and CHG.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Informed consent forms have been obtained from all subjects.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Consent for Publication"}}]}}